Metal-based antitumor compounds: beyond cisplatin
Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatm...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
2019
|
| Online Access: | http://hdl.handle.net/20.500.11937/74389 |
| _version_ | 1848763261012410368 |
|---|---|
| author | Simpson, Peter Desai, N. Casari, I. Massi, Massimiliano Falasca, Marco |
| author_facet | Simpson, Peter Desai, N. Casari, I. Massi, Massimiliano Falasca, Marco |
| author_sort | Simpson, Peter |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells. |
| first_indexed | 2025-11-14T11:00:39Z |
| format | Journal Article |
| id | curtin-20.500.11937-74389 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T11:00:39Z |
| publishDate | 2019 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-743892019-02-19T04:28:17Z Metal-based antitumor compounds: beyond cisplatin Simpson, Peter Desai, N. Casari, I. Massi, Massimiliano Falasca, Marco Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells. 2019 Journal Article http://hdl.handle.net/20.500.11937/74389 10.4155/fmc-2018-0248 restricted |
| spellingShingle | Simpson, Peter Desai, N. Casari, I. Massi, Massimiliano Falasca, Marco Metal-based antitumor compounds: beyond cisplatin |
| title | Metal-based antitumor compounds: beyond cisplatin |
| title_full | Metal-based antitumor compounds: beyond cisplatin |
| title_fullStr | Metal-based antitumor compounds: beyond cisplatin |
| title_full_unstemmed | Metal-based antitumor compounds: beyond cisplatin |
| title_short | Metal-based antitumor compounds: beyond cisplatin |
| title_sort | metal-based antitumor compounds: beyond cisplatin |
| url | http://hdl.handle.net/20.500.11937/74389 |